CN112226407A
|
|
NK cell-containing pharmaceutical composition and application thereof in treating cancer
|
CN111925451A
|
|
BCMA (brain cell activating antigen) -targeted Chimeric Antigen Receptor (CAR) and application thereof
|
CN112143697A
|
|
Method for promoting proliferation and differentiation of embryonic stem cells
|
CN112126624A
|
|
Method for inducing differentiation of embryonic stem cells into red blood cells
|
CN111920948A
|
|
Pharmaceutical composition comprising immune cells for treating cancer
|
CN112194723A
|
|
Application of immune cells in treating cancer
|
CN112062850A
|
|
TIM3 antibodies and their use in treating cancer
|
CN111944761A
|
|
Method for promoting differentiation and growth of epidermal stem cells
|
CN111704671A
|
|
OX40 antibodies and their use in treating cancer
|
CN111732660A
|
|
Combined treatment of cancer by mesenchymal stem cells and monoclonal antibodies
|
CN111671896A
|
|
Application of bone marrow mesenchymal stem cells and monoclonal antibody in combined treatment of cancer
|
CN111733133A
|
|
Method for promoting differentiation and growth of epidermal stem cells
|
CN111718898A
|
|
Method and reagent for improving stress tolerance of synovial membrane mesenchymal stem cells
|
CN111647067A
|
|
Application of AP-2alpha antibody combined medicine in preparation of medicine for treating cervical cancer
|
CN111635459A
|
|
anti-CD 47 antibodies and their use in treating cancer
|
CN111647084A
|
|
anti-c-MET antibodies and their use in treating cancer
|
CN111393525A
|
|
Monoclonal antibody of AP-2alpha and application thereof in preparing medicine for treating cervical cancer
|
CN111349178A
|
|
GPC 3-targeted Chimeric Antigen Receptor (CAR) and anticancer application thereof
|
CN111285935A
|
|
Antibody for specifically detecting BRAF gene mutation and application thereof in preparation of cancer detection kit
|
CN111303290A
|
|
Antibody specifically binding to liver cancer stem cells and application of antibody in preparation of liver cancer detection kit
|